Cargando…

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues

OBJECTIVE: The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, G-J, Tomasi, D, Volkow, N D, Wang, R, Telang, F, Caparelli, E C, Dunayevich, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010969/ https://www.ncbi.nlm.nih.gov/pubmed/23924756 http://dx.doi.org/10.1038/ijo.2013.145

Ejemplares similares

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
por: Guerdjikova, Anna I., et al.
Publicado: (2017)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Reduced Metabolism in Brain “Control Networks” following Cocaine-Cues Exposure in Female Cocaine Abusers
por: Volkow, Nora D., et al.
Publicado: (2011)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Methylphenidate Attenuates Limbic Brain Inhibition after Cocaine-Cues Exposure in Cocaine Abusers
por: Volkow, Nora D., et al.
Publicado: (2010)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
por: Welling, Mila S., et al.
Publicado: (2023)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
por: Sager, Jennifer E., et al.
Publicado: (2016)

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method
por: Apostolidi, Anna, et al.
Publicado: (2022)

Bupropion-Warfarin Combination: A Serious Complication
por: Bavle, Amar D., et al.
Publicado: (2013)

Food cue reactivity: Neurobiological and behavioral underpinnings
por: Kanoski, Scott E., et al.
Publicado: (2022)

Effects of depressive symptoms and peripheral DAT methylation on neural reactivity to alcohol cues in alcoholism
por: Wiers, C E, et al.
Publicado: (2015)

Effects of genotype and food on naltrexone exposure in adolescents
por: Stancil, Stephani L., et al.
Publicado: (2022)

Aging and Functional Brain Networks
por: Tomasi, Dardo, et al.
Publicado: (2011)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2020)

Association of Body Mass and Brain Activation during Gastric Distention: Implications for Obesity
por: Tomasi, Dardo, et al.
Publicado: (2009)

What Is Food Noise? A Conceptual Model of Food Cue Reactivity
por: Hayashi, Daisuke, et al.
Publicado: (2023)

Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans
por: Leighty, Anne E., et al.
Publicado: (2019)

Hyponatremia Associated with Bupropion
por: Kim, Chang Seong, et al.
Publicado: (2011)

Measures of Brain Connectivity and Cognition by Sex in US Children
por: Tomasi, Dardo, et al.
Publicado: (2023)

O-Benzoylnaltrexone
por: Yang, Rui, et al.
Publicado: (2013)

Association between striatal dopamine D(2)/D(3) receptors and brain activation during visual attention: effects of sleep deprivation
por: Tomasi, D, et al.
Publicado: (2016)

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
por: Wharton, Sean, et al.
Publicado: (2021)

Combination of Naltrexone and Isotretinoin for the Treatment of Darier Disease
por: Costa, Tomás, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_od5o811s9sno7ji0ju7683mpd3